Physician profile
Mark E Henderson
NPI 1760902498
$1,320.00
in general payments reported to CMS, 2019-2025
18 companies · $579 in 2025
The $579 reported for 2025 was more than what 76% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $24.35 · 2021: $62.89 · 2022: $62.12 · 2023: $261 · 2024: $331 · 2025: $579.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,171.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,170.64 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $241.60 | 2023-2025 | |
| Merck Sharp & Dohme LLC | $192.01 | 2021-2025 | Verquvo |
| Astrazeneca Pharmaceuticals LP | $187.44 | 2020-2025 | Farxiga, Airsupra, Breztri |
| Lilly USA, LLC | $124.00 | 2020-2024 | Mounjaro, Zepbound |
| Novo Nordisk INC | $114.15 | 2023-2025 | Ozempic, Rybelsus, Wegovy |
| Corcept Therapeutics | $80.51 | 2024-2025 | Korlym |
| Xeris Pharmaceuticals, INC. | $79.52 | 2023 | Gvoke Hypopen |
| Amgen INC. | $54.47 | 2025 | Evenity, Prolia |
| Organon LLC | $46.58 | 2025 | Nexplanon |
| Biohaven Pharmaceutical Holding Company LTD. | $45.82 | 2022 | |
| Supernus Pharmaceuticals, INC. | $35.91 | 2024-2025 | Qelbree |
| Axsome Therapeutics, INC. | $19.97 | 2025 | |
| Sanofi-Aventis U.S. LLC | $18.86 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $17.78 | 2025 | |
| Glaxosmithkline, LLC. | $16.05 | 2024 | Trelegy Ellipta |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ardelyx, INC. | $15.46 | 2025 | Ibsrela |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $14.98 | 2025 | Caplyta |
| Pfizer INC. | $14.89 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Henderson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.